Open AccessCorrecting Nature: Targeting dysfunctional carbohydrate processing
Author(s) -
Graeme Horne
Publication year - 2012
Publication title -
the biochemist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 7
eISSN - 1740-1194
pISSN - 0954-982X
DOI - 10.1042/bio03401026
Subject(s) - dysfunctional family , business , revenue , advertising , drug , pharmaceutical industry , marketing , commerce , industrial organization , pharmacology , medicine , accounting , psychiatry
The pharmaceutical industry has experienced remarkable growth over the last few decades fuelled by sales revenues of blockbuster drugs such as Lipitor® (Pfizer), Plavix® (BMS/Sanofi-Aventis) and Advair® (GlaxoSmithKline). However, as these drugs approach patent expiries, the era of the blockbuster drug can be considered to be coming to an end.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom